Skip to main content

Postoperative Bowel & Ileus Management — Drug-Class Hub

Postoperative ileus (POI) can delay recovery after GU operations involving bowel — urinary diversion (ileal conduit, orthotopic neobladder, Mainz, Indiana), augmentation cystoplasty, continent catheterizable channels, and large pelvic reconstruction with bowel resection or interposition. Reported POI rates vary with definition, procedure, approach and ERAS pathway; it is an important cause of prolonged admission and readmission.[1][2][3] Different bowel segments recover at different rates, but clinical ileus is multifactorial. Do not use fixed segment-recovery times to dismiss persistent vomiting, pain or distention; obstruction, leak, infection and metabolic disturbances need consideration.[5]

The clinical workflow for post-op constipation and ileus management (bowel prep, ERAS prophylactic regimens, stepped escalation and the PAMORA framework) lives at Postoperative constipation & ileus.

For adjacent topics see NSAIDs & analgesics (opioid-sparing analgesia), ERAS, and Nausea & vomiting.

Drug-Class Overview at a Glance​

Class / agentMechanismBest-supported roleEvidence strength
PAMORA — AlvimopanPeripheral μ-opioid receptor antagonist (blocks GI opioid effect without crossing BBB)Accelerate GI recovery after surgery including bowel resection / primary anastomosisModerate-certainty cystectomy recovery evidence; strongest for predominantly open cohorts[6][7][8]
Prokinetic — MetoclopramideD₂ antagonist; sensitizes upper GI to AChAntiemetic with modest upper-GI prokinetic effectLow-certainty, inconsistent evidence for POI resolution[11][12][13]; labeled for adult PONV prophylaxis when nasogastric suction is undesirable[10]
Prokinetic — NeostigmineAChE inhibitorAcute colonic pseudo-obstruction (Ogilvie) — a guideline-supported role after failed supportive careModerate-quality ACPO evidence ; limited evidence for routine POI[21][22][23]
Stimulant laxative — BisacodylProdrug → antiabsorptive, secretory, prokinetic on colonSelected postoperative constipation regimen; not treatment of obstructionIn elective colorectal surgery, 2025 ERAS says bisacodyl may be used to prevent postoperative ileus .[17][40]
Stimulant laxative — SennaAnthraquinone stimulantAlternative postoperative stimulantOne pelvic-reconstruction RCT tested senna plus docusate against placebo[20]
Stool softener — DocusateAnionic surfactant—Pasay et al. studied administration after education, not postoperative efficacy[19]
Anti-foaming — SimethiconeSurfactant (gas coalescence)Comfort measure for bloating; not prokineticNegative RCT[15]
Osmotic laxative — PEGOsmotic draw into colonOption for ordinary postoperative constipation when oral intake is appropriateThe urologic cohort pooled diverse agents, with traditional Chinese medicines the largest group[29]
Non-pharmacologic — Gum chewingVagal cholinergic "sham feeding"Optional adjunct when oral intake / airway safety permitSmall cystectomy randomized / cohort studies and broader GI synthesis[24][25][26]
Non-pharmacologic — CoffeeMultimodal colonic stimulation (beyond caffeine)Optional adjunct when oral intake / airway safety permitNetwork meta-analysis; 2025 colorectal ERAS guidance rates coffee evidence low and its recommendation weak[26][28][40]

1. Alvimopan — Selected Perioperative GI Recovery​

In a randomized placebo-controlled trial of 280 radical-cystectomy patients receiving postoperative intravenous opioid patient-controlled analgesia, primarily at centers using open laparotomy, alvimopan accelerated GI-2 recovery and shortened hospital stay.[6] The 2024 AUA/ASCO/SUO guideline recommends μ-opioid antagonist therapy after radical cystectomy unless contraindicated .[37] The US indication is recovery after surgery that includes partial bowel resection with primary anastomosis, not every operation near bowel.[4][6]

Mechanism​

Peripherally acting μ-opioid receptor antagonist (PAMORA): K_i 0.4 nM at the μ receptor, with slower dissociation kinetics than other μ ligands. Has limited central penetration, so it blocks opioid-induced GI dysmotility while preserving central analgesia from perioperative opioids.[4]

Dosing​

  • 12 mg PO 30 min – 5 h before surgery, then 12 mg PO twice daily starting POD 1 until discharge[4]
  • Maximum 15 total doses or 7 days — whichever comes first
  • Inpatient use only through the Alvimopan REMS Program[4]

Efficacy in radical cystectomy with urinary diversion​

Lee 2014 multicenter RCT (280 randomized; 277 modified intention-to-treat):[6]

  • GI-2 recovery (first solid food and BM): 5.5 vs 6.8 days (HR 1.8; p < 0.0001)[6]
  • Length of stay: reduced by approximately 2.7 days
  • POI-related morbidity: 8.4% versus 29.1%[6]
  • Cochrane 2017 found moderate-certainty evidence for faster GI recovery / discharge, based on this single eligible trial[7]

Real-world and ERAS-integrated data​

  • Belle 2019 Vizient database (n = 7,472 cystectomies 2014–2016): alvimopan utilization increased from 35% to 59%; associated with decreased perioperative morbidity (10.5% vs 19.2%; p = 0.027)[8]
  • Hanna 2021: in sequential retrospective cystectomy cohorts, ERAS plus alvimopan (n = 48) versus ERAS alone (n = 102) was associated with shorter median LOS (7 vs 9 days; p = 0.012) and less POI (14.6% vs 36.3%; p = 0.005). Median time to first BM was 4 days in both ERAS groups, versus 5 days before ERAS (overall p = 0.018).[1]
  • Small retrospective subgroups detected no difference[1][3]

Alhashemi 2021 systematic review: low-to-moderate certainty evidence for open bowel resection and open cystectomy with diversion; very-low-certainty for MIS. This is the framework for patient selection; the strongest direct cystectomy evidence comes from predominantly open surgery with postoperative IV opioid analgesia; contemporary robotic / opioid-sparing pathways may have different absolute benefit.[9]

Safety and the FDA boxed warning​

FDA Boxed Warning. A 12-month trial of alvimopan 0.5 mg BID for chronic non-cancer pain showed a greater incidence of myocardial infarction vs placebo. A causal relationship has not been established, and this imbalance was not observed in short-term trials of surgery that included bowel resection (alvimopan 12 mg twice daily for up to 7 days, n = 1,142 vs placebo, n = 1,120).[4] Alvimopan is therefore restricted to short-term inpatient use only (≤ 15 doses, ≤ 7 days) through the REMS program.

The label contraindicates alvimopan after therapeutic opioid doses for more than seven consecutive days immediately before treatment. Patients given more than three opioid doses in the week before surgery were not studied in the postoperative-ileus trials; if treated, monitor for abdominal pain, nausea, vomiting and diarrhea.[4] It separately says use is not recommended in severe hepatic impairment, ESRD, complete GI obstruction / surgery to correct it, and pancreatic or gastric anastomoses. Monitor for GI adverse effects with lesser renal / hepatic impairment.[4]

In trials of surgery that included bowel resection, the most common adverse reaction occurring more often with alvimopan was dyspepsia (1.5% vs 0.8% with placebo).[4]

Other PAMORAs​

For opioid-induced constipation outside the immediate perioperative window, especially in patients on chronic opioids for pelvic pain, IC/BPS flares or oncologic survivorship, methylnaltrexone, naloxegol and naldemedine are the relevant agents. See the PAMORA framework on Postoperative constipation & ileus for indication-by-indication detail.

2. Metoclopramide — Antiemetic with Modest Upper-GI Prokinetic Effect​

Mechanism​

D₂-receptor antagonist that sensitizes GI tissues to ACh, with increased gastric antral contractions, pyloric relaxation and duodenal or jejunal peristalsis. Has little effect on colonic motility.[10]

Evidence in urinary-diversion surgery​

Donat 1999 (81 after cystectomy with diversion; 27 intervention, 54 concurrent controls) combined IV metoclopramide with NG removal planned before 24 hours (achieved in 78%):[12]

  • Faster return of bowel sounds: 2.9 vs 4.0 days (p = 0.0002)
  • Earlier solid food tolerance: 6.7 vs 7.9 days (p = 0.04)
  • Lower atelectasis: 15% versus 33% in the combined intervention[12]

The older review and EAST 2019 systematic guideline did not find evidence that metoclopramide hastens ileus resolution.[11][13] EAST could not recommend for or against it because evidence was limited.[11][13]

Current ERAS role​

  • Included in approximately 44% of protocols in a 2020 review[14]
  • Primary role is PONV prophylaxis with modest prokinetic adjunct, not primary POI prevention
  • Do not schedule repeated doses solely because bowel function has not returned; identify the cause

Dosing and safety​

ElementDetail
Adult PONV label example10 or 20 mg IM once near the end of surgery [10]
Renal adjustment for repeated injection dosesCurrent cited label: CrCl ≤60 mL/min → half the normal dose; ESRD → one quarter. Follow the exact indication / product [10]
FDA boxed warningPotentially irreversible tardive dyskinesia; risk increases with cumulative exposure and duration (the label advises avoiding more than 12 weeks in diabetic gastroparesis); a single dose can still cause acute dystonic or other extrapyramidal reactions
Important exclusionsPrior TD / dystonic reaction, GI hemorrhage / obstruction / perforation, pheochromocytoma / catecholamine-releasing paraganglioma, epilepsy or hypersensitivity
Other precautionsAvoid in Parkinson disease and with other drugs that can cause extrapyramidal symptoms (including antipsychotics), strong CYP2D6 inhibitors (including bupropion, fluoxetine and paroxetine), or monoamine oxidase inhibitors; assess sedation and neurologic reactions.[10] For repeated doses in Child-Pugh B or C, reduce the dose by half. After bowel anastomosis, weigh the label's theoretical suture-line pressure concern before use.

These dose and safety points come from the April 2026 injection label, not from proof of postoperative-ileus efficacy.[10]

3. Neostigmine — For Acute Colonic Pseudo-Obstruction, Not Routine POI​

Neostigmine has a specific, defined role in urology: treatment of acute colonic pseudo-obstruction (ACPO, or Ogilvie syndrome), which can complicate major pelvic GU surgery. It is not appropriate for routine POI prophylaxis.[23]

Mechanism​

Acetylcholinesterase inhibition increases ACh at muscarinic receptors throughout the GI tract and stimulates colonic motility.

Evidence in ACPO — strong​

ASCRS 2021 gives neostigmine after failed supportive treatment a strong 1B recommendation.[22] ASGE 2020 recommends neostigmine for eligible patients after failed or unsuitable conservative care, or when perforation risk warrants escalation.[21][22]

  • Ponec 1999 small placebo-controlled RCT: 10/11 patients receiving 2 mg IV neostigmine initially responded, versus 0/10 with placebo; median response time was four minutes.[22] Recurrence and need for further decompression remained possible
  • Meta-analysis: single IV 2–5 mg dose, 60–94% success; recurrence 0–31%; overall long-term response 69–100%[22]
  • Second dose for initial nonresponders: effective in 40–100%[22]

ACPO treatment boundaries​

Exclude mechanical obstruction and assess for ischemia or perforation before pharmacologic decompression. For ACPO with cecal diameter <12 cm and no fever, leukocytosis, significant pain, peritonitis or signs of ischemia or perforation, initial care includes correcting electrolytes and precipitating medications, bowel rest, and appropriate decompression; avoid oral osmotic and stimulant laxatives while the colon is dilated.[21][22] Persistent symptoms after approximately 48–72 hours or increasing dilation require gastroenterology / surgical reassessment; clinical deterioration, peritonitis or suspected ischemia or perforation is not an automatic neostigmine indication.[21][22]

For eligible ACPO after conservative treatment fails, ASGE recommends 2 mg IV over 3–5 minutes, with continuous cardiac-rhythm and respiratory monitoring and immediate access to atropine.[21] Bronchospasm, bradycardia, vomiting, salivation and cramping can occur. Repeat dosing or infusion / alternative routes require specialist-directed selection. ASGE also offers colonoscopic decompression with a decompression tube as an alternative after failed conservative care, and ASCRS recommends considering it when neostigmine is contraindicated or ineffective.[21][22]

Intestinal or urinary obstruction and hypersensitivity are contraindications.[21] Bradycardia, asthma, renal insufficiency, recent MI, acidosis and peptic ulcer disease are important relative contraindications in the ASGE guidance.[21]

Routine POI — not indicated​

The Traut 2008 Cochrane review of systemic prokinetics for POI found neostigmine "might show effects" on recovery time, but the evidence was limited to small trials of moderate-to-poor quality. Neostigmine has no established role in routine POI prophylaxis; ASCRS recommends it for confirmed ACPO that persists despite supportive care.[21][22][23]

3a. Other Agents — Methylnaltrexone, Erythromycin, Intravenous Lidocaine, and Nasogastric Decompression​

AgentWhat to knowStatus
MethylnaltrexonePeripheral μ-antagonist labeled only for opioid-induced constipation (chronic non-cancer pain; advanced illness). Contraindicated in known or suspected GI obstruction or increased risk of recurrent obstruction (perforation risk); the Relistor label also reports GI perforation in patients with opioid-induced constipation and advanced illness who had vulnerable bowel conditions including Ogilvie syndrome.[31] A retrospective cohort of 110 patients with established POI (28 treated) found no difference in time to resolution (9.9 vs 11.4 days), LOS or decompression time.[32]Off-label for POI, with no established treatment benefit[32]; contraindicated with known or suspected GI obstruction[31]; the 2025 elective-colorectal ERAS guideline recommends against its use to prevent ileus (moderate-quality evidence).[40]
ErythromycinMotilin agonist. EAST 2019 (low-certainty evidence) found no effect on ileus resolution and made no recommendation for or against it.[11]Not established for POI
IV lidocaine infusionOpioid-sparing multimodal adjunct. The Cochrane review (68 trials, 2018) graded effects on ileus and time to first bowel movement as very-low-certainty and dose and duration varied widely (1–5 mg/kg/h).[33] The pragmatic ALLEGRO trial (557 analyzed, minimally invasive colectomy; 1.5 mg/kg ideal body weight IV bolus over 20 min, then 1.5 mg/kg ideal body weight/h (maximum 120 mg/h) for 6–12 h) found no difference in GI-3 recovery at 72 hours (57.3% vs 59%).[34]—
Nasogastric tubeRoutine postoperative NG decompression after cystectomy is unnecessary in uncomplicated recovery. A 43-patient cystectomy RCT summarized in the 2013 ERAS guidance found no difference in morbidity, bowel transit or LOS with removal at 12 hours versus after first flatus.[35] That guidance also discusses gum chewing, PONV prophylaxis and minimally invasive surgery as components of multimodal ileus prevention.[35] A 2025 cystectomy surgeon consensus advises removal at surgery's end unless an intraoperative complication warrants retention.[36] Reinsert for persistent vomiting or distention.Selective use

Opioid-sparing analgesia (scheduled non-opioid agents, regional or local techniques) reduces the opioid exposure that drives POI and is the foundation on which the agents above operate; see NSAIDs & analgesics.

4. Stimulant Laxatives — Bisacodyl and Senna​

Bisacodyl is one stimulant option for postoperative constipation once oral / rectal administration is appropriate:

Mechanism​

Prodrug hydrolyzed by intestinal brush-border enzymes into an active metabolite with antiabsorptive, secretory and prokinetic effects on the colon.[16]

Evidence​

Zingg 2008 colorectal RCT (200 randomized; 169 analyzed: bisacodyl 83, placebo 86):[17]

  • GI-3 index (mean of times to first flatus, defecation and solid-food tolerance): median 3.0 vs 3.7 days (p = 0.007)[17]
  • First defecation: 3.0 vs 4.0 days (p = 0.001)
  • No difference in first flatus or solid-food tolerance
  • No difference in morbidity / mortality

Wallström 2014 systematic review classified bisacodyl's effect on overall bowel motility as "uncertain" in colorectal surgery, with accelerated defecation but no consistent improvement in other GI recovery parameters.[18]

ASCRS 2024 chronic-constipation guidance recommends osmotic laxatives as first-line medical therapy and allows stimulants such as bisacodyl for rescue or second-line use. It notes a lack of randomized trials of the anthraquinone stimulants (senna, cascara, aloe) in chronic constipation.[16]

Dose and use​

Zingg's colorectal RCT used 10 mg oral bisacodyl twice daily from the day before surgery through POD 3; a separate 20-patient colectomy RCT randomized patients without spontaneous defecation by POD 3 to a 10 mg rectal suppository or placebo, with a second dose after 12 hours if needed.[17][38] Route and timing depend on the operation, oral tolerance and exclusion of obstruction or acute abdominal pathology. Rectal agents after anorectal reconstruction require the operative team’s plan.[17]

Senna: alternative anthraquinone stimulant. Patel 2010 compared senna plus docusate (48 patients) with placebo (45 patients) after pelvic reconstructive surgery; mean time to first BM was 3.00 vs 4.05 days (p < 0.002).[20]

5. Docusate — De-prescribe as Monotherapy​

Mechanism​

Anionic surfactant; emulsifies stool. No prokinetic activity.

Evidence — negative​

Pasay et al. summarized earlier docusate literature but studied a prescribing education intervention, not drug efficacy.[19] A 2023 urogynecologic review found that multiple-agent laxative regimens may reduce bothersome constipation more than docusate alone.[39] It does not lessen associated symptoms (abdominal cramps) or improve stool-evacuation perception.

The inertia problem​

A single-facility study by Lee et al., cited by Pasay et al., found that docusate accounted for 64% of laxative administrations there; Pasay et al. discussed low cost and historical practice as possible drivers of continued use.[19] An educational intervention successfully reduced docusate use.[19]

Practical recommendation​

Docusate has little supporting efficacy evidence.

6. Simethicone — Comfort Measure, Not Prokinetic​

Mechanism​

Non-absorbed surfactant reducing surface tension of GI gas bubbles and facilitating coalescence and passage. Does not stimulate motility.

Evidence​

SPOT trial (n = 118, colorectal surgery), a randomized POI study:[15]

  • First flatus: 25.2 vs 26.7 h (p = 0.98)
  • First BM: 41.1 vs 42.9 h (p = 0.91)
  • LOS: 4.5 vs 4.0 days (p = 0.63)

Practical role​

Symptomatic relief of bloating and gas pain only. It is generally well tolerated, but should not delay evaluation of worsening distention or pain.

7. Osmotic Laxatives and Prophylactic Laxative Use​

Wahafu 2025 real-world cohort (n = 1,724 urologic-cancer surgery patients):[29]

  • Within seven postoperative days, constipation occurred in 92/748 (12.3%) patients given prophylactic laxatives versus 319/748 (42.7%) managed after symptoms developed in the matched analysis (HR 0.24; 95% CI 0.19–0.30; p < 0.001).[29]

When ordinary postoperative constipation is anticipated and oral intake is appropriate, PEG 3350 17 g daily is one common osmotic option; a single stimulant can be selected or added if needed. See the workflow at Postoperative constipation & ileus.

8. Non-Pharmacologic Adjuncts — Gum Chewing and Coffee​

Optional adjuncts for patients able to chew / swallow safely and whose postoperative diet permits them. Consider tolerance, aspiration risk and bladder-symptom triggers.

Gum chewing ("sham feeding")​

Vagal cholinergic stimulation and increased saliva production.

  • Kouba 2007 (102 cystectomy patients, sequential cohorts rather than randomization): flatus 2.4 versus 2.9 days; BM 3.2 versus 3.9 days; LOS difference was not statistically significant[24]
  • Choi 2011 (cystectomy n = 60, open and robotic): flatus 57.1 vs 69.5 h; BM 76.7 vs 93.3 h[25]
  • Sinz 2023 NMA (32 RCTs, n = 4,999 across gum, coffee and caffeine comparisons; 26 trials studied gum): gum chewing reduced time to flatus by 11 h, time to defecation by 18 h and LOS by 0.9 d[26]
  • ASCRS/SAGES ERAS gives sham feeding (gum chewing for ≥ 10 min, 3–4× daily) after colorectal surgery a strong recommendation (1B); most trials used sugar-free gum.[27]

Coffee​

Coffee may stimulate bowel activity through several mechanisms.

  • Sinz 2023 NMA — coffee reduced time to defecation by 13 h and LOS by 1.5 d[26]
  • Zheng 2025 meta reported favorable decaffeinated-coffee rankings in colorectal studies.[28]

Evidence Summary — Interpretation Across Studies​

ComponentWhat the evidence supportsMain limitation
AlvimopanFaster GI recovery and shorter admission in the cystectomy RCT[6][7]Predominantly open, opioid-PCA setting; Cochrane contained the same single trial
ERAS and NG avoidanceWilliams IPD analysis associated ERAS with shorter LOS; NG avoidance was one associated component[30]The −8.7-day NG coefficient is not a randomized treatment effect
Gum / coffeePossible small recovery gains; gum is included in colorectal ERAS guidance[24][25][26][27][28]Mixed procedures and study quality; optional when clinically appropriate
LaxativesA colorectal bisacodyl RCT shortened time to defecation[17][29]—
Metoclopramide / simethicone / docusateNo established routine ileus-resolution benefit[11][15][19]—
NeostigmineEffective for selected ACPO after supportive measures fail[21][22]Requires the correct diagnosis, monitored administration and assessment for complications

Cross-Reference — What's Covered on the Perioperative Constipation/Ileus Page​

To avoid duplication, these topics live at Postoperative constipation & ileus:

TopicWhere it lives
Bowel preparation (mechanical ± oral antibiotics, by GU procedure type)Perioperative-care page
ERAS prophylactic bowel regimen (selected laxative regimen, NG avoidance, early feeding)Perioperative-care page
Stepped management of established ileus — NG, bowel rest, imaging, surgical vs medical thresholdsPerioperative-care page
PAMORA framework beyond alvimopan — methylnaltrexone, naloxegol, naldemedine for chronic OICPerioperative-care page
Drug-class pharmacology and doses for each agentThis article
Alvimopan boxed warning / contraindications / REMS detailThis article
Neostigmine ACPO protocolThis article

Keep the two separate: workflow on the perioperative-care page, drug-class pharmacology here.

Practical Pearls​

  • Distinguish constipation, postoperative ileus and ACPO. Escalating laxatives or prokinetics without reassessing the diagnosis can delay recognition of obstruction, leak or ischemia.
  • Use alvimopan within its inpatient label / REMS limits. The strongest cystectomy evidence comes from a predominantly open cohort; evaluate the likely absolute benefit within the current pathway.[4][6][7]
  • Neostigmine requires appropriate monitoring and rescue capability. Worsening pain, peritonitis or clinical deterioration requires urgent reassessment rather than reflex dosing.[21][22]
  • ERAS is a coordinated pathway. Selective NG use remains appropriate for established indications.[30]

See Also​

References​

1. Hanna P, Regmi S, Kalapara A, et al. "Alvimopan as part of the enhanced recovery after surgery protocol following radical cystectomy is associated with decreased hospital stay." Int J Urol. 2021;28(6):696–701. doi:10.1111/iju.14546

2. Pang KH, Groves R, Venugopal S, Noon AP, Catto JWF. "Prospective implementation of enhanced recovery after surgery protocols to radical cystectomy." Eur Urol. 2018;73(3):363–371. doi:10.1016/j.eururo.2017.07.031

3. Nakamura M, Tsuru I, Izumi T, et al. "Advantages of enhanced recovery after surgery program in robot-assisted radical cystectomy." Sci Rep. 2023;13(1):16237. doi:10.1038/s41598-023-43489-w

4. Alvimopan capsules: US prescribing information and REMS requirements. Primary source. Accessed September 12, 2026.

5. Bragg D, El-Sharkawy AM, Psaltis E, Maxwell-Armstrong CA, Lobo DN. "Postoperative ileus: recent developments in pathophysiology and management." Clin Nutr. 2015;34(3):367–376. doi:10.1016/j.clnu.2015.01.016

6. Lee CT, Chang SS, Kamat AM, et al. "Alvimopan accelerates gastrointestinal recovery after radical cystectomy: a multicenter randomized placebo-controlled trial." Eur Urol. 2014;66(2):265–272. doi:10.1016/j.eururo.2014.02.036

7. Sultan S, Coles B, Dahm P. "Alvimopan for recovery of bowel function after radical cystectomy." Cochrane Database Syst Rev. 2017;5:CD012111. doi:10.1002/14651858.CD012111.pub2

8. Belle JD, Pooli A, Oleynikov D, Deibert CM. "Alvimopan usage increasing following radical cystectomy." World J Urol. 2019;37(6):1151–1155. doi:10.1007/s00345-018-2476-3

9. Alhashemi M, Hamad R, El-Kefraoui C, et al. "The association of alvimopan treatment with postoperative outcomes after abdominal surgery: a systematic review across different surgical procedures and contexts of perioperative care." Surgery. 2021;169(4):934–944. doi:10.1016/j.surg.2020.11.025

10. Metoclopramide injection: US prescribing information, revised April 2026. Primary source. Accessed September 12, 2026.

11. EAST. Promotility Agents for the Treatment of Ileus in Adult Surgical Patients. Practice management guideline, 2019. Primary source. Accessed September 12, 2026.

12. Donat SM, Slaton JW, Pisters LL, Swanson DA. "Early nasogastric tube removal combined with metoclopramide after radical cystectomy and urinary diversion." J Urol. 1999;162(5):1599–1602. doi:10.1016/s0022-5347(05)68175-x

13. Bungard TJ, Kale-Pradhan PB. "Prokinetic agents for the treatment of postoperative ileus in adults: a review of the literature." Pharmacotherapy. 1999;19(4):416–423. doi:10.1592/phco.19.6.416.31040

14. Wessels F, Lenhart M, Kowalewski KF, et al. "Early recovery after surgery for radical cystectomy: comprehensive assessment and meta-analysis of existing protocols." World J Urol. 2020;38(12):3139–3153. doi:10.1007/s00345-020-03133-y

15. Springer JE, Elkheir S, Eskicioglu C, et al. "The effect of simethicone on postoperative ileus in patients undergoing colorectal surgery (SPOT), a randomized controlled trial." Int J Surg. 2018;56:141–147. doi:10.1016/j.ijsu.2018.06.011

16. Alavi K, Thorsen AJ, Fang SH, et al. "The American Society of Colon and Rectal Surgeons clinical practice guidelines for the evaluation and management of chronic constipation." Dis Colon Rectum. 2024;67(10):1244–1257. doi:10.1097/DCR.0000000000003430

17. Zingg U, Miskovic D, Pasternak I, et al. "Effect of bisacodyl on postoperative bowel motility in elective colorectal surgery: a prospective, randomized trial." Int J Colorectal Dis. 2008;23(12):1175–1183. doi:10.1007/s00384-008-0536-7

18. Wallström A, Frisman GH. "Facilitating early recovery of bowel motility after colorectal surgery: a systematic review." J Clin Nurs. 2014;23(1-2):24–44. doi:10.1111/jocn.12258

19. Pasay D, Guirguis M, Shkrobot R, Slobodan J, Bresee L. "Association of dissemination of an educational communication tool with docusate administration." JAMA Intern Med. 2017;177(10):1433–1436. doi:10.1001/jamainternmed.2017.3605

20. Patel M, Schimpf MO, O'Sullivan DM, LaSala CA. "The use of senna with docusate for postoperative constipation after pelvic reconstructive surgery: a randomized, double-blind, placebo-controlled trial." Am J Obstet Gynecol. 2010;202(5):479.e1–5. doi:10.1016/j.ajog.2010.01.003

21. Naveed M, Jamil LH, Fujii-Lau LL, et al. "American Society for Gastrointestinal Endoscopy guideline on the role of endoscopy in the management of acute colonic pseudo-obstruction and colonic volvulus." Gastrointest Endosc. 2020;91(2):228–235. doi:10.1016/j.gie.2019.09.007

22. Alavi K, Poylin V, Davids JS, et al. "The American Society of Colon and Rectal Surgeons clinical practice guidelines for the management of colonic volvulus and acute colonic pseudo-obstruction." Dis Colon Rectum. 2021;64(9):1046–1057. doi:10.1097/DCR.0000000000002159

23. Traut U, Brügger L, Kunz R, et al. "Systemic prokinetic pharmacologic treatment for postoperative adynamic ileus following abdominal surgery in adults." Cochrane Database Syst Rev. 2008;(1):CD004930. doi:10.1002/14651858.CD004930.pub3

24. Kouba EJ, Wallen EM, Pruthi RS. "Gum chewing stimulates bowel motility in patients undergoing radical cystectomy with urinary diversion." Urology. 2007;70(6):1053–1056. doi:10.1016/j.urology.2007.07.048

25. Choi H, Kang SH, Yoon DK, et al. "Chewing gum has a stimulatory effect on bowel motility in patients after open or robotic radical cystectomy for bladder cancer: a prospective randomized comparative study." Urology. 2011;77(4):884–890. doi:10.1016/j.urology.2010.06.042

26. Sinz S, Warschkow R, Tarantino I, Steffen T. "Gum chewing and coffee consumption but not caffeine intake improve bowel function after gastrointestinal surgery: a systematic review and network meta-analysis." J Gastrointest Surg. 2023;27(8):1730–1745. doi:10.1007/s11605-023-05702-z

27. Irani JL, Hedrick TL, Miller TE, et al. "Clinical practice guidelines for enhanced recovery after colon and rectal surgery from the American Society of Colon and Rectal Surgeons and the Society of American Gastrointestinal and Endoscopic Surgeons." Surg Endosc. 2023;37(1):5–30. doi:10.1007/s00464-022-09758-x

28. Zheng L, Zhang X, Ma B, Yuan Y, Yang H. "Efficacy of non-pharmacological interventions for the restoration of postoperative intestinal motility of patients with colorectal cancer: a systematic review and meta-analysis of randomized controlled trials." Int J Colorectal Dis. 2025;40(1):176. doi:10.1007/s00384-025-04968-w

29. Wahafu W, Yang F, Yang T, et al. "Prophylactic laxative use for postoperative constipation in urological cancer: a real-world cohort study." World J Urol. 2025;43(1):698. doi:10.1007/s00345-025-06050-0

30. Williams SB, Cumberbatch MGK, Kamat AM, et al. "Reporting radical cystectomy outcomes following implementation of enhanced recovery after surgery protocols: a systematic review and individual patient data meta-analysis." Eur Urol. 2020;78(5):719–730. doi:10.1016/j.eururo.2020.06.039

31. Relistor (methylnaltrexone bromide) tablets and injection: US prescribing information, Salix Pharmaceuticals, revised May 2026. Primary source. Accessed September 24, 2026.

32. Beavers J, Orton L, Atchison L, et al. "The Efficacy and Safety of Methylnaltrexone for the Treatment of Postoperative Ileus." Am Surg. 2022;88(3):409–413. doi:10.1177/00031348211048825

33. Weibel S, Jelting Y, Pace NL, et al. "Continuous intravenous perioperative lidocaine infusion for postoperative pain and recovery in adults." Cochrane Database Syst Rev. 2018;6(6):CD009642. doi:10.1002/14651858.CD009642.pub3

34. Paterson H, Vadiveloo T, Innes K, et al. "Intravenous lidocaine for gastrointestinal recovery after colorectal surgery: the ALLEGRO placebo-controlled randomised trial and cost-effectiveness analysis." Health Technol Assess. 2026;30(19):1–51. doi:10.3310/GJHP2321

35. Cerantola Y, Valerio M, Persson B, et al. "Guidelines for perioperative care after radical cystectomy for bladder cancer: Enhanced Recovery After Surgery (ERAS) society recommendations." Clin Nutr. 2013;32(6):879–887. doi:10.1016/j.clnu.2013.09.014

36. Albisinni S, Orecchia L, Mjaess G, et al. "Enhanced recovery after surgery for patients undergoing radical cystectomy: Surgeons' perspectives and recommendations ten years after its implementation." Eur J Surg Oncol. 2025;51(3):109543. doi:10.1016/j.ejso.2024.109543

37. American Urological Association, American Society of Clinical Oncology, Society of Urologic Oncology. "Treatment of non-metastatic muscle-invasive bladder cancer: AUA/ASCO/SUO guideline (2017; amended 2020, 2024)." 2024. Official guideline.

38. Wiriyakosol S, Kongdan Y, Euanorasetr C, Wacharachaisurapol N, Lertsithichai P. "Randomized controlled trial of bisacodyl suppository versus placebo for postoperative ileus after elective colectomy for colon cancer." Asian J Surg. 2007;30(3):167–172. doi:10.1016/S1015-9584(08)60017-2

39. Woodbury CF, Coughlin AC, Dubois B, Romanova A. "Prevention of postoperative constipation in urogynecology patients: A systematic review." Urogynecology (Phila). 2023;29(2):175–182. doi:10.1097/SPV.0000000000001281

40. Gustafsson UO, Rockall TA, Wexner S, et al. "Enhanced Recovery After Surgery (ERAS) Society 2025 Guidelines for Perioperative Care in Elective Colorectal Surgery." Surgery. 2025;184:109397. doi:10.1016/j.surg.2025.109397